In September 2026 the BMA has published a position statement on semaglutide (Wegovy®) for cardiovascular risk reduction under NICE TA1152. It recognises semaglutide as an important development, with evidence showing a reduction in major cardiovascular events. However, the BMA is clear that implementation must be supported by appropriate funding, commissioning and infrastructure, and that general practice should not be expected to deliver this work within existing resources. This is aligned with our LMC position from August 2026 .
